Six months after surviving a patent challenge involving its $3.2 million gene therapy, Sarepta faces a new lawsuit from another gene therapy developer claiming the approved treatment infringes its active patents.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,